A Phase Ib/II Study of ST-1898 to Evaluate the Efficacy and Safety in Patients With Renal Cell Carcinoma (RCC)
Latest Information Update: 21 Nov 2023
At a glance
- Drugs ST 1898 Beijing Scitech Mq Pharmaceuticals (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Beijing Scitech-Mq Pharmaceuticals
Most Recent Events
- 21 Nov 2023 New trial record